Regeneron Asks F.D.A. for Emergency Approval for Drug That ...

The New York Times - 08 Oct 2020
The company said that doses of the unproven treatment would be available for 50000 patients. It's impossible to know whether it helped the president.

Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth

Reuters - 25 Apr 2024
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth ...

Regeneron, Mammoth Launch In Vivo CRISPR Gene Editing Collaboration

Genetic Engineering & Biotechnology News - 25 Apr 2024
Regeneron, Mammoth Launch In Vivo CRISPR Gene Editing Collaboration ...

Regeneron signs Mammoth gene editing deal worth $100M upfront

Fierce Biotech - 25 Apr 2024
Regeneron signs Mammoth gene editing deal worth $100M upfront ...

Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors

MarketWatch - 26 Apr 2024
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors ...

Sales of Roche's juggernaut Vabysmo rout the analyst consensus

FiercePharma - 24 Apr 2024
Sales of Roche's juggernaut Vabysmo rout the analyst consensus ...

Regeneron and Mammoth announce gene editing partnership worth $370m per target

PMLiVE - 26 Apr 2024
Regeneron and Mammoth announce gene editing partnership worth $370m per target ...

Regeneron and Mammoth team up to develop gene editing therapies

Pharmaceutical Technology - 26 Apr 2024
Regeneron and Mammoth team up to develop gene editing therapies ...

Regeneron Fails to Quash Skin Cancer Drug Warning Suit (Correct)

Bloomberg Law - 26 Apr 2024
Regeneron Fails to Quash Skin Cancer Drug Warning Suit (Correct) ...

Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Delivery

BioSpace - 25 Apr 2024
Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Delivery ...

Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines

MedCity News - 25 Apr 2024
Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines ...

AbbVie's Rinvoq shows superiority to Regeneron's Dupixent in study

XM - 25 Apr 2024
AbbVie's Rinvoq shows superiority to Regeneron's Dupixent in study ...

Regeneron inks $100M deal to develop gene-editing therapies

Crain's New York Business - 26 Apr 2024
Regeneron inks $100M deal to develop gene-editing therapies ...

Regeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to Watch

Investopedia - 11 Apr 2024
Regeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to Watch ...

AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study

Reuters - 25 Apr 2024
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study ...

Head-to-head, it's AbbVie's Rinvoq over Regeneron's Dupixent

FiercePharma - 26 Apr 2024
Head-to-head, it's AbbVie's Rinvoq over Regeneron's Dupixent ...

Regeneron builds new venture arm with $500M commitment to invest in biotech and beyond

Fierce Biotech - 15 Apr 2024
Regeneron builds new venture arm with $500M commitment to invest in biotech and beyond ...

Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day

MarketWatch - 24 Apr 2024
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day ...

Regeneron hit with FDA rejection for blood cancer therapy

Pharmaceutical Technology - 26 Mar 2024
Regeneron hit with FDA rejection for blood cancer therapy ...

Regeneron to defend against DOJ complaint on drug-price manipulation

Reuters - 15 Apr 2024
Regeneron to defend against DOJ complaint on drug-price manipulation ...

Regeneron